Skip to main content

Table 1 Baseline characteristics by gender of all COVID-19 cases referred to healthcare centres in Mashhad City from Feb 14, to May 11, 2020

From: Epidemiological characteristics and initial spatiotemporal visualisation of COVID-19 in a major city in the Middle East

Reference All patients Males Females p-value
Number of patients (%) 4000 (100) 2352 (58.8) 1648 (41.2)  
Median age of the patients 57.0 years 56 .0 years 58 .0 years 0.0104*
Age range 39.0–71.0 39.0–70.0 39.0–73.0
Days from onset to hospital admission 2.0 2.0 2.0 0.9783
Range of days 1.0–4.0 1.0–4.0 0.0–4.0
Days from hospital admission to outcome 5.0 5.0 5.0 0.4751
Range of days 2.0–8.0 2.0–8.0 2.0–8.0
Demographics & clinical characteristics Number (%) Number (%) Number (%)  
Co-morbidity
 Diabetes 491 (12.27) 252 (10.71) 239 (14.50) 0.0003*
 CVD 805 (20.12) 404 (17.2) 401 (24.3) < 0.0001*
 Liver disorders 112 (2.80) 61 (2.59) 51 (3.09) 0.3444
 CRD 155 (3.87) 95 (4.04) 60 (3.64) 0.5206
 Nervous diseases 99 (2.47) 64 (2.72) 35 (2.12) 0.2314
 COPD 236 (5.90) 115 (4.89) 121 (7.34) 0.0011*
 Malignancy (any) 99 (2.47) 59 (2.50) 40 (2.42) 0.8706
Initial symptoms
 Fever 2177 (54.42) 1308 (55.61) 869 (52.73) 0.0716
 Cough 2377 (59.42) 1383 (58.80) 994 (60.31) 0.337
 Dyspnoea 2777 (69.42) 1606 (68.28) 1171 (71.05) 0.0609
 Weakness 778 (19.45) 452 (19.21) 326 (19.78) 0.6574
 Myalgia 574 (14.35) 331 (14.07) 243 (14.74) 0.5507
 Dizziness 338 (8.45) 206 (8.75) 132 (8.0) 0.4020
 Sore throat 434 (10.85) 262 (11.13) 172 (10.43) 0.4819
 Sputum 74 (1.85) 37 (1.57) 37 (2.24) 0.1206
 Diarrhoea 137 (3.42) 79 (3.35) 58 (3.51) 0.7834
 Nausea or vomiting 332 (8.30) 182 (7.74) 150 (9.10) 0.1238
 Headache 325 (8.12) 184 (7.82) 141 (8.55) 0.4038
 Chest pain 318 (7.95) 181 (7.70) 137 (8.30) 0.4773
 Abdominal pain 70 (1.75) 32 (1.36) 38 (2.30) 0.0248*
 Arthralgia 235 (5.87) 133 (5.65) 102 (6.19) 0.4792
 Pharyngitis 49 (1.22) 27 (1.14) 22 (1.33) 0.5967
 Conjunctivitis 30 (0.75) 17 (0.72) 13 (0.78) 0.8117
 Abnormal chest X-ray 1059 (26.47) 617 (26.23) 442 (26.82) 0.6786
End-points
 ICU admission 502 (12.55) 307 (13.05) 195 (11.83) 0.2516
 Ventilator 772 (19.30) 449 (19.09) 323 (19.59) 0.6878
 Coma 24 (0.60) 16 (0.68) 8 (0.48) 0.4322
Exposure history (last 14 days)
 Travel 83 (2.07) 58 (2.46) 25 (1.51) 0.0382*
 Exposed at medical centres 323 (8.07) 185 (7.86) 138 (8.37) 0.5615
 Exposed to possibly infected individuals 267 (6.68) 155 (6.59) 112 (6.79) 0.7973
 Exposed to animals 175 (4.37) 118 (5.02) 57 (3.46) 0.0177*
 Being healthcare staff 281 (7.03) 158 (6.71) 123 (7.46) 0.3636
Disease severity 0.0404*
 General 3228 (80.70) 1927 (81.93) 1301 (78.94)
 Severe 748 (18.70) 414 (17.60) 334 (20.27)
 Critical 24 (0.60) 11 (0.47) 13 (0.79)
Disease outcome 0.0437*
 Non-survivor 707 (17.67) 430 (18.3) 277 (16.8)
 Survivor 2236 (55.90) 1334 (56.7) 902 (54.7)
 Ongoing care 1057 (26.43) 588 (25.0) 469 (28.5)
COVID-19 confirmation 0.0118*
 PCR confirmation 1325 (33.1) 816 (34.7) 509 (30.9)
 Clinical confirmation 2675 (66.9) 1536 (65.3) 1139 (69.1)
  1. CVD Cardiovascular Diseases, CRD Chronic Renal Diseases, COPD Chronic Obstructive Pulmonary Diseases, ICU Intensive Care Unit. *Significant values